

- Delivery of 5-aminosalicylic acid (5-ASA) to the colonic mucosa is required for effective management of ulcerative colitis (UC)
- This study examines the 5-ASA dissolution profiles of several mesalamine formulations: APRISO[®] extended-release capsules (Salix Pharmaceuticals, Inc., Raleigh, NC, USA); ASACOL[®] MR tablets (Procter & Gamble Pharmaceuticals UK Ltd., Surrey, UK) and ASACOL[®] HD tablets (Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA); MEZAVANT XL[®] tablets (Shire US Inc., Wayne, PA, USA); PENTASA[®] tablets (Ferring Pharmaceuticals, Ltd., West Drayton, UK); and SALOFALK[®] tablets (Dr Falk Pharma UK Ltd., Bourne End, UK)
- Tested at physiologically relevant pH values (1.0, 6.0, and 6.8) to simulate the gastrointestinal tract, mesalamine formulations exhibited variability in 5-ASA dissolution profiles.

This summary slide represents the opinions of the authors. Sponsorship, article processing charges, and the open access charge for this study were funded by the sponsor, Shire Development LLC. Under the direction of the authors, writing and editorial support was provided by Jason Jung, PhD, of MedErgy. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by MedErgy. Shire Development LLC provided funding to MedErgy for support in writing and editing this manuscript. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).